<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845348</url>
  </required_header>
  <id_info>
    <org_study_id>TD0307.03</org_study_id>
    <nct_id>NCT03845348</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases</brief_title>
  <acronym>TD0307</acronym>
  <official_title>Đánh giá hiệu quả điều trị viêm da dầu ở đầu của dầu gội Thái Dương 3 và Thái Dương 7 (A Randomized, Double Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy Shampoos TD03 and TD07 in Scalp Diseases)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunstar Joint Stock Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Big Leap Clinical Research Support Joint Stock Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunstar Joint Stock Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 %&#xD;
      among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with&#xD;
      successful rate reaching nearly 95%. This trial is going to evaluate the efficacy of getting&#xD;
      rid of dandruff as well as the safety of the investigational products in comparison to a&#xD;
      reference (ketoconazole 2%) during a 4-week treatment period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scalp Conditions are common chronic skin inflamations with the occurence rate of 1 - 5 %&#xD;
      among the population. TD03 shampoo and TD07 shampoo are widely used to avoid hair loss with&#xD;
      successful rate reaching nearly 95%. With herbal ingredients including Gleditsia, Morus alba,&#xD;
      Ocimum tenuiflorum, Oroxylum indicum, Ageratum conyzoides, the investigational products could&#xD;
      reduce the severity of inflamation, infection and help to prevent hair loss. This trial is&#xD;
      planning to evaluate the efficacy of the IPs in terms of inflamation reduction, dandruff&#xD;
      reduction on subjects using the IPs compared to a reference (ketoconazole 2%).&#xD;
&#xD;
      The trial is intended to last for 18 months with subject visits and 3 arms (122 subjects per&#xD;
      arm). The first arm receive TD3 while TD7 is provided to the second arm in comparison to the&#xD;
      placebo of the last arm. It will be conducted at National Hospital of Dermato - Venerology,&#xD;
      Vietnam.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in IGA scale at 4 week-treatment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change from baseline in IGA scale at 4 week-treatment of TD3 and TD7 compared to that of Ketoconazole 2% shampoo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The numbers of subjects with AE/SAE</measure>
    <time_frame>4 weeks</time_frame>
    <description>The numbers of subjects with AE/SAE as defined in the protocol.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Scalp Dermatitis</condition>
  <arm_group>
    <arm_group_label>TD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD3, bi-daily x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TD7, bi-daily x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoconazole 2%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketoconazole 2% shampoo bi-daily x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TD03</intervention_name>
    <description>Shampoo TD 3 days</description>
    <arm_group_label>TD3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TD07</intervention_name>
    <description>Shampoo TD 7 days</description>
    <arm_group_label>TD7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 2% Shampoo</intervention_name>
    <description>Ketoconazole 2% Shampoo</description>
    <arm_group_label>Ketoconazole 2%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years old and signed the ICF.&#xD;
&#xD;
          -  Diagnosed with head skin inflamtion with IGA &lt;= 3.&#xD;
&#xD;
          -  Voluntary sign the ICF before any procedures.&#xD;
&#xD;
          -  No hypersentivity to the IP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use oral antifungal 1 month prior to the trial participation or topical antifungal 2&#xD;
             weeks prior to the trial participation.&#xD;
&#xD;
          -  Suffering chronic or acute diseases that may affect the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuong TM Pham</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Hospital of Dermatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Van Nguyen Thi Hong, MSC</last_name>
    <phone>(+84) 916451269</phone>
    <email>vannh@thaiduong.com.vn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nationa Hospital of Dermatology</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Pham Thi Minh</last_name>
      <phone>04.3852.1179</phone>
    </contact>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>February 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

